Services@ibtbioservices.com

IBT BIOSERVICES Anti-EBOV GP

murine/human chimeric monoclonal antibody (13F6)

Catalog #: 0201-022

Lot #: 1411004

Immunogen: Venezuelan equine encephalitis virus replicons encoding Ebola virus (EBOV) glycoprotein (GP) was used to generate the original mouse monoclonal antibody.

Description: A murine / human chimeric IgG produced in *N. benthamiana* and is reactive to EBOV GP. The antibody detects GP in virus-like particles (VLP) and recombinant GP without the transmembrane region (rGPdTM).

Supplied: 100 μg is supplied at a concentration of **5.32 mg/mL**. No preservative is added.

Purification: Antibody is purified using immobilized protein A.

Clonality: Murine variable, human constant of the IgG1 isotype.

Relevance: The antibody can be used for detection of EBOV GP. A mixture of all three anti-EBOV GP chimeric antibodies was protective against lethal challenge in a nonhuman primate study (Olinger *et al.* PNAS 2012, vol. 109, no. 44, 18030-18035).

Recommended Dilutions:

ELISA: Assay-dependent dilution

 $\it WB:$ Assay-dependent dilution. Internal QC demonstrates good detection when using antibody at 0.5 μg/mL.


Storage: 2-3 weeks +4°C, -20°C long term

Cross Reactivity: No cross-reactivity was observed to Sudan virus (SUDV) or Marburg Virus (MARV) rGPdTM. A few faint bands were visible in SUDV VLP and MARV VLP.

Related Products:

IBT provides a wide array of anti-filovirus specific antibodies, recombinant proteins and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Western Blot Data:



Western blots were detected under reduced conditions with anti-EBOV GP chimeric antibody at 0.5 μ g/mL and visualized using an anti-human IgG-HRP conjugate and TMB membrane substrate. GP is visualized in Baculovirus-expressed EBOV VLP (lane 1) and in EBOV rGPdTM expressed in insect cells (lane 4). No cross-reactivity against SUDV or MARV rGPdTM proteins was observed (lanes 5,6). A few faint bands were visible in the Baculovirus-expressed SUDV and MARV VLP (lanes 2,3).

ELISA Data:

	OD (F0	
	OD 650 nm	
Antibody	EBOV VLP	EBOV rGPdTM
(µg/mL)	@ 10 μg/mL	@ 1 μg/mL
2.0000	3.690	3.655
0.6325	3.669	3.628
0.2000	3.632	3.610
0.0632	3.382	3.466
0.0200	2.659	3.099
0.0063	1.516	2.128
0.0020	0.629	1.064
0.0006	0.277	0.481
0.0002	0.139	0.211
0.0000	0.081	0.094

VLPs were diluted to 10 μ g/mL and rGPdTM proteins were diluted to 1 μ g/mL in PBS for plate coating. Anti-EBOV GP chimeric antibody was serially diluted semi-log from 2.0 μ g/mL and incubated on the coated plates. Washed plates were detected with anti-human IgG-HRP conjugate and TMB substrate. OD₆₅₀ is reported above.

Additional testing results:

Test Method	Result	
Endotoxin	0.26 EU/mg	
Bioburden	0 CFU/mL	
Size Exclusion HPLC	91.8% monomer	
	1.3% High Molecular Weight	
	6.9% Low Molecular Weight	
Residual Host Cell DNA	0.88 ng/mg	
Residual Host Cell Protein	Below the limit of detection	
	<3.125 ng/mL	

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.